Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Open label study of sorafenib

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Swedish Medical Center
• Collaborators: Amgen; Bayer; Onyx Pharmaceuticals
• Treatments: Sorafenib

Criteria

Inclusion Criteria:

• Age > 18

• Life expectancy > 12 weeks

• Biopsy-proven BAC or adenocarcinoma

• Willing to provide smoking status

• Selected IIIB or stage IV cancer that is incompletely resected or unresectable

Exclusion Criteria:

• O2 saturation < 88% on room air

• Pregnant or nursing women

• Surgery or radiation therapy within 4 weeks of starting study

• Major heart condition within 6 months of starting therapy

• Certain concomitant medications prohibited